Head-to-head · WeighScore
Andrew Meds vs Spry
By GLP-1 ScorecardUpdated
Score comparison
Andrew Meds has the higher recorded score — 67.1/100 to 59.2/100.
Andrew Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Andrew Meds shows standard monthly prices and lower twelve-month figures for both compounded injections. Ask what is due up front and what happens if you leave early.
Before you choose
Before comparing the headline prices, the Andrew Meds review and the Spry review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Andrew Meds vs TeleClinic and Breeze Meds vs Spry compare each of them with another graded program, and the list of alternatives to Andrew Meds ranks the programs closest to Andrew Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Oak review covers one graded close to these two, at 63.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Andrew Meds | Spry |
|---|---|---|
| WeighScore | 67.1/100 | 59.2/100 |
| Grade | C | C |
| Site position | #182 | #380 |
| Semaglutide | $199/mo (standard compounded plan; $149/mo figure on a 12-month plan) | $199/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (standard compounded plan; $229/mo figure on a 12-month plan) | $299/mo (starting dose, compounded) |
| Coverage | 50 states and D.C. advertised; medication availability varies | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Lists separate prices for both injections and both plan options
- Names the independent medical group and three pharmacy partners
- Describes billing at the start of each plan cycle
What to consider
- Twelve-month figures do not establish the selected debit schedule or early-exit cost
- The FAQ says refund requests are handled case by case
- Confirm your dispensing pharmacy and medication availability
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
What to consider
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.